UY27857A1 - Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica" - Google Patents

Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica"

Info

Publication number
UY27857A1
UY27857A1 UY27857A UY27857A UY27857A1 UY 27857 A1 UY27857 A1 UY 27857A1 UY 27857 A UY27857 A UY 27857A UY 27857 A UY27857 A UY 27857A UY 27857 A1 UY27857 A1 UY 27857A1
Authority
UY
Uruguay
Prior art keywords
treatment
inflammatory response
syndrome
systemic inflammatory
medicinal product
Prior art date
Application number
UY27857A
Other languages
English (en)
Inventor
Dr Uwe Ries
Dr Wolfgang Wienen
Dr Uwe Schuhly
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27857A1 publication Critical patent/UY27857A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la utilización de determinados bencimidazoles para la preparación de un medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica" y, en particular de la sepsis.
UY27857A 2002-06-20 2003-06-18 Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica" UY27857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227668A DE10227668A1 (de) 2002-06-20 2002-06-20 Arzneimittel zur Behandlung des systemic inflammatory response syndrome

Publications (1)

Publication Number Publication Date
UY27857A1 true UY27857A1 (es) 2003-12-31

Family

ID=29719307

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27857A UY27857A1 (es) 2002-06-20 2003-06-18 Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica"

Country Status (12)

Country Link
EP (1) EP1517687B1 (es)
JP (1) JP4249128B2 (es)
AR (1) AR041180A1 (es)
AT (1) ATE365038T1 (es)
AU (1) AU2003278945A1 (es)
CA (2) CA2489545A1 (es)
DE (2) DE10227668A1 (es)
ES (1) ES2289305T3 (es)
PE (1) PE20040575A1 (es)
TW (1) TW200407130A (es)
UY (1) UY27857A1 (es)
WO (1) WO2004000310A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110115578A (ko) 2008-12-30 2011-10-21 트롬보로직 에이피에스 장기 부전이 발달할 증가된 위험이 있는 중증 질환 환자의 확인 방법 및 이의 치료를 위한 화합물
CA2822350A1 (en) 2010-12-21 2012-06-28 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa
CN102659687B (zh) * 2012-03-16 2014-10-08 西南大学 苯并咪唑胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6407130B1 (en) * 1999-11-10 2002-06-18 Boehringer Ingelheim Pharma Kg Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity
US7196095B2 (en) * 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors

Also Published As

Publication number Publication date
DE50307521D1 (de) 2007-08-02
TW200407130A (en) 2004-05-16
CA2489545A1 (en) 2003-12-31
WO2004000310A1 (de) 2003-12-31
JP2006514603A (ja) 2006-05-11
EP1517687A1 (de) 2005-03-30
JP4249128B2 (ja) 2009-04-02
AR041180A1 (es) 2005-05-04
CA2715558A1 (en) 2003-12-31
EP1517687B1 (de) 2007-06-20
DE10227668A1 (de) 2004-01-08
ATE365038T1 (de) 2007-07-15
PE20040575A1 (es) 2004-10-05
AU2003278945A1 (en) 2004-01-06
ES2289305T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
PA8564001A1 (es) Aza-arilpiperazinas
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
DE60326859D1 (de) Arzneimittelverabreichung
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
RU2007122391A (ru) S-миртазапин для лечения приливов
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
ECSP077843A (es) Tratamiento o prevención del prurito
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AR061352A1 (es) El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv
UY27857A1 (es) Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica"
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
SE0000303D0 (sv) Novel compounds
AR067351A1 (es) Combinacion de picotamida con nafronil
SE0203817D0 (sv) New composition
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126